ProCE Banner Activity


ACR 2021: New Data on axSpA and axPsA Treatment Options and Health Disparities in Patients With Axial Disease

Conference Coverage
Clinical Thought
Get my take on key studies from ACR 2021 on axSpA and axPsA treatment options and health disparities in patients with axial disease.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: December 22, 2021

Expiration: December 21, 2022

No longer available for credit.



Atul Deodhar

Atul Deodhar, MD

Professor of Medicine
Medical Director
, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by an educational grant from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

This program is intended for dermatology, rheumatology and pediatric physicians, and other healthcare professionals who manage patients with psoriatic disease

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize the latest research findings from ACR 2021 related to axSpA and axPsA management
  • Translate key findings from recent investigations into practical applications in the management of patients with axSpA and axPsA
  • Incorporate key findings and strategies regarding health disparities to reduce disparities and improve outcomes in patients with axial disease


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Atul Deodhar, MD

Professor of Medicine
Medical Director
, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon

Atul Deodhar, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Aurinia, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Lilly, MoonLake Immunotherapeutics, Novartis, Pfizer, and UCB and funds for research support from AbbVie, GlaxoSmithKline, Lilly, Novartis, Pfizer, and UCB.

Staff Disclosure


Ruth Cohen,

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Courtney Duval, PharmD, BCACP

Scientific Director

Courtney Duval, PharmD, BCACP, has no relevant conflicts of interest to report.

Elaine P. Seeskin,

Managing Editor, HIV
Clinical Care Options, LLC

Elaine Seeskin has no relevant conflicts of interest to report.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 22, 2021, through December 21, 2022:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this educational program is to increase the knowledge and competence of learners in evaluating the latest data for axSpA and axPsA from ACR 2021 and integrating the most clinically important data to clinical practice for appropriate management of each condition.